

## Etiologies of Premature ovarian failure (POF)

Pr Philippe Bouchard  
Endocrinology  
Hôpital Saint-Antoine  
Université Pierre et Marie Curie, EA 1533 Paris



### Premature Ovarian Failure/ Insufficiency (POF/POI)

- Amenorrhoea > 6 months
- FSH > 40 mIU/ml
- Arbitrarily < Age 40
- 1% of all women

Goswami D *Hum Reprod Update*  
2005

## Premature Ovarian Insufficiency

### Disease name and synonyms

Premature ovarian failure (POF; POFI; OMIM 311360);  
Hypergonadotropic ovarian failure; Menopausa precoce.


### Included diseases

POF2 (OMIM #300511); POF3 (OMIM #608996)

### Definition

Premature ovarian failure is defined as a primary ovarian defect characterized by absent menarche (primary amenorrhea) or premature depletion of ovarian follicles/ arrested folliculogenesis before the age of 40 years (secondary amenorrhea).

## Ovarian Follicular loss



## The factors setting the age of menopause

### Environmental factors :

Women who smoke reach menopause 2 years earlier than non smokers

*Midgette 1990 Epidemiology 1; 1479-480*

*Bromberger 1997 Am J Epidemiol 145; 124-133 Gold 2001 Am J Epidemiol 15; 634-639*

## The factors setting the age of menopause

### Environmental factors :




Animal models of ovarian failure

AhR  $-/-$  mice

Dioxin/aryl hydrocarbon receptor knock-out mice

At birth Twice the number of primordial follicles as compared to controls

*Robles R Endocrinology 2000; 141: 450*



## POI

- Identify women/ families with POI and risk of transmission of a genetic disorder

---

---

---

---

---

---

## POF

Etiology unknown  
in more than 90% of cases,  
apart from  
surgery  
chemotherapy, radiotherapy  
and Turner syndrome

---

---

---

---

---

---

## Genes and POF

Familial cases  
In 15 - 20% of cases

---

---

---

---

---

---


## Heterogeneous Origin

- Iatrogenic origin (surgery, chemotherapy, radiations);
- Autoimmune, including polyglandular autoimmune syndrome, as well as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) due to mutations in *AIRE* gene;
- Infections (e.g. herpes zoster, cytomegalovirus);
- Chromosome X defects:
  - Turner syndrome
  - Fragile X syndrome (*FMR1* gene premutation)
  - Monogenic defects
  - Syndromic defects:
    - Congenital disorders of glycosylation (CDG, former named carbohydrate-deficient glycoprotein syndrome (recessive)
    - Galactosemia (recessive)
    - Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) (female-limited, dominant)
    - Pseudohypoparathyroidism (PHP) type Ia (parental imprinting: maternal inheritance)
- Isolated defects:
  - Follicle stimulating hormone (FSH) receptor mutations (*FSHR*), (recessive)
  - Luteinizing hormone (LH) receptor mutations (*LHR*), (recessive)
  - FOXL2 (transcription factor involved in BPES) mutations (female-limited defect, dominant)
  - Bone morphogenetic protein 15 (*BMP15*) mutations (female-limited defect, heterozygous mutation)
  - Idiopathic


Table 1. Genes implicated in FOI

Categories	Chromosome	Gene	Gene locus
Mutations identified	X chromosome genes	<i>FMR1</i>	Xq27.3
		<i>FMR2</i>	Xq8
		<i>BMP15</i>	Xp11.2
	Autosomal genes	<i>FOXL2</i>	3q22-q23
		<i>FSHR</i>	2p11-p16
		<i>LH receptor</i>	2p11
		<i>FSH beta variant</i>	1p13
		<i>LH beta</i>	19q13.32
		<i>Inhibin A</i>	2q13-q16
		<i>GALP</i>	9q13
		<i>AIRE</i>	21q22.3
		<i>EIF2B2, -4, and -5</i>	14q24.3, 2p23.3, 3q27
		<i>NOGGIN</i>	17q22
		<i>POLG</i>	1Sq25
		<i>DIA1P2</i>	Xq22
Candidate genes	X chromosome genes	<i>DFRRX</i>	Xp11.4
		<i>XPN/EP2</i>	Xq25
		<i>ZFX</i>	Xp22.3-p21.3
		<i>FSHPRH</i>	Xq22
		<i>XIST</i>	Xq13.2
	Autosomal genes	<i>WT1</i>	11p13
		<i>ATM</i>	11q22.3
Mutations not identified	X chromosome genes	<i>AT2</i>	Xq22-q23
		<i>c-Kit</i>	4q12
		<i>SOX3</i>	Xq26-q27
	Autosomal genes	<i>MIS</i>	19p13.3-13.2

## Early follicular loss : Turner



## X Chromosome




## POF patients without clinical Turner phenotype


Saint-Antoine, Lille, A Béclère

354 patients

40 control women

PHRC AOR1066





## X chromosome study

- Characterisation of the translocation breakpoints
    - breakpoints fall in POF2
    - In poorly transcribed regions

=> Not an X-linked gene interruption

⇒ Position effect  
on flanking X-linked genes  
or genes flanking the autosomal breakpoints

## X Chromosome




Figure 1. POF critical regions and candidate genes on the human X chromosome.


0017-5203(2004)10:1;1-2  
Printed in U.S.A.

The Journal of Clinical Endocrinology & Metabolism 119:1:171-172  
Copyright © 2004 by The Endocrine Society  
doi:10.1210/jc.2004-018


Editorial: BMP15—The First True Ovarian Determinant Gene on the X-Chromosome?

L Layman


## BMP15 : Inverdale ewe



Galloway, *Nat Genet* 2000; 25 : 279-283  
Shimasaki S *Endocr Rev* 2004; 25 : 72



Di Pasquale Am J Hum Genet 2004; 75



*Di Pasquale Am J Hum Genet 2004; 75*

Gene	Sequence variation	AA change
BMP15	788insTCT	Ins263L
	443T > C	L148P
	538G > A	A180T
	852C > T	S284S
	831T > C	T277T
	468G > A	V156V

*Laissye P, EJE 2006, 154: 1-7*


N=166 POF women variants 9/166

Patient no.	Gene variation	Protein variation	Phenotype
36	c. 538G>A	p. A180T	SA
73	c. 202C>T	p. R68W	SA
79	c. 538G>A	p. A180T	SA
92	c. 538G>A	p. A180T	SA
112	c. 538G>A	p. A180T	SA
113	c. 538G>A	p. A180T	PA
118	c.704 A>G	p. Y235C	PA
124	c.788insTCT	p.262insLeu	PA
125	c.788insTCT	p.262insLeu	SA

Di Pasquale J Clin Endocrinol Metab 2006

- BMP15 polymorphisms or mutations?
- In vitro* studies are necessary

## X Chromosome



## *FMR1* gene

- X fragile syndrome
- 1st cause of mental retardation in boys
- CGG triplets 5'UTR region


---

---

---

---

---



---

---

---

---

---

N<41  
intermediary 41-59  
premuted 60-200 (1:590 women)  
mutated > 200

---

---


---

---

---


Expression of *FMR1* in normal women, premutation carriers, and full mutation carriers. Figure adapted from Hagerman and Hagerman (10).

### Expression of the Fragile X Gene



Wittenberger. *FMR1* premutation. *Fertil Steril* 2007.

### Premutated women



C Welt 2004 JCEM 80 : 4969

20% of women with a premutation have POF

Sherman Am J Med Genet 2000; 97: 189

A premutation is present in 3% of sporadic POF cases  
A premutation is present in 13% of familial POF cases

Conway G Hum Reprod 1998; 13: 1184  
Sullivan AK Hum Reprod 2005; 20: 402


No linear correlation between the number of triplets and POF

Highest risk if 80-100 triplets

Sullivan AK *Hum Reprod* 2005; 20: 402  
Ennis S *Eur J Hum Genet* 2006; 14: 253

## 1. BPES: definition


- Blepharophimosis
- Ptosis
- Epicantus inversus



### Syndrome de BPES Blepharophimosis, Ptosis, Epicanthus inversus Syndrome


- Type I : POF and eyelids abnormalities
  - No testicular phenotype
- Type II : Eyelid abnormalities,  
No Gonadal Phenotype

### Blepharophimosis Epicanthus Syndrome




### BALANCED TRANSLOCATION

□ translocation patient t(3;4) (q23; p15.2)









Fukushima et al., Am J Med Genet, 1991.

### FOXL2



d'après De Baere et al., 2001






## FOXL2: gene in sporadic POF ?

- 100 POF patients without BPES: no mutation  
*De Baere et al., 2002*
- 70 POF patients without BPES : 2 mutations ?  
*Harris et al., 2002*
- 120 POF patients without BPES : no mutation  
*Bodega et al., 2004*

## 2-GDF9 : growth differentiation factor 9



GDF9 -/- mouse model  
*Elvin Mol Endocrinol 1999; 13 :1018*

## GDF9

- 127 POF women
- 220 controls
- 8 variants : mutations ou polymorphisms?

*Dixit H Menopause, 2005*

N=203

GDF9	557C > A	S186Y	→ Menarche 9,5 Regular menstrual cycles 21 days Amenorrhea 33 FSH = 104 mUI/L
447C > T		T149T	
546G > A		E182E	
Biopsy : absence of follicles			
<i>EJE 2006, 154: 1-7</i>			

d)

GDF9




<i>H. sapiens (S186Y)</i>	C N L M I K E P K S <b>S</b> R T L G R A P Y S
<i>H. sapiens (WT)</i>	C N L M I K E P K S <b>S S S</b> R T L G R A P Y S
<i>P. troglodytes</i>	C N L M I K E <b>S</b> K S <b>S S</b> R T L G R A P Y S
<i>D. novemcinctus</i>	X X X X X X X K S <b>S S S</b> E A F P R A P Y S
<i>O. garnettii</i>	C N L V I K D P K S <b>S S S</b> K T L L R A P Y S
<i>M. mulatta</i>	C N L M I K E P K F <b>S S S</b> K T L L R A P Y S
<i>P. anubis</i>	C N L M I K E P K F <b>S S S</b> K T L H R A L Y S
<i>C. jacchus</i>	C N L M M K E P K F <b>S S S</b> K T L P R G E Y S
<i>B. taurus</i>	C N L V I K E P E F <b>S S S</b> K T L P R A P Y S
<i>C. hircus</i>	C N L V I K E P E F <b>S S S</b> K T L P R A P Y S
<i>O. aries</i>	C N L V I K E P E F <b>S S S</b> K T L P R A P Y S
<i>C. familiaris</i>	C H L V I K E P E F <b>S S S</b> W T P Q R A P S L
<i>M. domestica</i>	C H L V V K E P E C <b>S S S</b> P F C G S P R S
<i>T. vulpecula</i>	C Y L I V K E P E C <b>S S S</b> P S Y F R S P Q P
<i>S. acrofa</i>	C G L V V K E P E L I S <b>S</b> K T L P K A P Y S
<i>R. norvegicus</i>	C D L V V K E P M <b>S S S</b> K A T P R A P Y S
<i>M. musculus</i>	C D L V V K E A M S S I G R A P P R A P Y S
<i>G. gallus</i>	C H L S V K E H D F S S Q V C P S V S H S

### 3-FSH receptor

- Families with > 3 cases of primary amenorrhea
- North of Finland
- Linkage analysis :  
chromosome 2p

Aittomaki K, Cell 1995; 82: 959





**Mr R, 34 , Infertility**

- puberty: 13-14
- 88 kg, 165 cms: BMI 32kg/m<sup>2</sup>
- Testes volume 20-25 mL
- Reduced penis size
- P2-P3, Shaving x 1 / month
- Spermogram :
  - Small Volume : 0.35 et 0.5 ml
  - 3.2 millions sp / ejaculate
  - Low vitality  
( 20 et 14%)

---

---

---

---

---

---

• Hormonal Assessment:

- Testosterone: 0.9 nmol/L (N: 11-40)
- LH: 30 U/L (N: 0.5-11)
- FSH: 10.3 U/L (N: 0.8-13)
  
- Inhibin B: 153 ng/mL (N: 135-350)
- AMH: 222 pmol/L (N: 26-100)
  
- PRL: 19.5 ng/L, E2: < 5 pg/mL

---

---

---

---

---

---

• Testicular US:

Right T: 49 x 28 mm, Left T: 50x30 mm.

• Caryotype 46 XY (170 cellules)

• Negative hCG Test :

- Testostérone: from 2.8nmol/L to 2.2 nmol/L @ 96h
- LH: 17 U/L , FSH: 9 U/L

---


---

---


---

---

---



## Résultats (I):






**homozygote mutation g → a en -1 du site accepteur d'épissage de l'intron 10 avant le début de l'exon 11.**

## RESULTS

- 1- The intron 10 acceptor splice site appeared to be an inefficient site. We had to cut out certain sequences from exon 11, since they were used as preferred splice acceptors for exon 10.
- 2- The mutation makes the acceptor site even worse: less product of the right size AND another splice product is found: **24 bp downstream another splice site is used, that results in a deletion of the first 8 AA of exon 11!** This does not happen in the wt.

So: the mutations causes less LH receptor to be produced + the mutations causes a different LH receptor protein to be produced.



### Mrs EF (II6), 42 homozygote

- Menarche : 16 ans,
- Regular cycles (28 days) until age 20 ans followed by oligomenorrhea (2 -6 months).
- At age 30 CC treatment
  - => follicular development up to 10, 12, et 15mm, with no endometrial growth beyond 8 mm
  - => No d'ovulation : progesterone= 0.6ng/ml.

---

---

---

---

---

---

### Mme EF (II6), 42 ans, homozygote

- Two IVF attempts:
  - => multifollicular development (14 follicles , 9-14mm & 18 follicles, 9-25 mm) after Rec FSH
  - =>estradiol: 910 et 1260 nmol/L
  - => Following hCG , No Oocyte retrieval on 2 occasions.
- Progestin induced menstruation
- After treatment cessation: at age 42, : persistance of irregular spontaneous menses

On day 2: E2: 138 pg /mL, LH: 9 U/L, FSH: 9.5 U/L.

---

---

---

---

---

---

### Mrs JF (II3), 53, homozygote

- Menarche: 16-17
- Oligomenorrhea 90 to 240 day cycles
- Failure of several attempts of ovarian stimulation
- Menopause @ 51 ans

### Mrs MD ( II5), 44, heterozygote:

- Menarche: 13-14
- Regular cycles,
- G5P2,

---

---

---

---

---

---

**Table II.** Autoimmune polyglandular syndromes and POF

APS type	Inheritance	Autoimmune involvement	Age group	Incidence of POF
APS I	Autosomal recessive caused by a mutation in the autoimmune regulator ( <i>AIRE</i> ) gene on chromosome 21	Chronic mucocutaneous candidiasis, adrenal and parathyroid failure	Children age 3–5 years or in early adolescence	17–50% (Ahonen <i>et al.</i> , 1990)
APS II (more common)	Polygenic, characterized by dominant inheritance and association with HLA DR3	Primary adrenal failure (Addison's disease) with autoimmune thyroid disease (Schmidt's syndrome) and/or type 1 diabetes (Carpenter's syndrome) Thyroid failure and other immunological syndromes with exclusion of Addison's disease	Adults in the third or fourth decade	3.6–10% (Bettelle <i>et al.</i> , 2004)
APS III	Apart from the absence of adrenal failure, no clinical differences between types II and III have been described		Adults	

## GENES IDENTIFIED IN VERY FEW CASES

In 2008 many candidate genes

**TABLE 1. Established Mendelian disorders (and OMIM number) with ovarian failure as one component\***

- Ataxia-telangiectasia (#208900)
- Bloom syndrome (#210900)
- Cockayne syndrome (#216400)
- Martsolf syndrome (#212720)
- Nijmegen syndrome (#251260)
- Rothmund-Thomson syndrome (#268400)
- Werner syndrome (#277700)

## POF

### • Autosomes

- *FSHR*
- *FOXL2*
- *GDF9*
- *ATM*
- *AIRE*
- *NOBOX*
- *GALT*
- *EIF2B*
- *NSB1*
- *DMC1*
- Parathyroid responsive B1 gene
- *FIGLA*
- *Progesterone receptor membrane component-1 (PGRMC1)*


### • X linked

- X Monosomy
  - X,XX mosaicism
  - X ring
  - Triple X
  - X Deletions
  - X, autosome translocations
- *FMR1*
- *BMP15* .....

## Perspectives

### Genome scanning of familial cases

## Families IOP - France




## A genome-wide linkage scan in a Dutch family identifies a premature ovarian failure susceptibility locus

R.A. Oldenburg<sup>1</sup>, M.F. van Dooren<sup>1</sup>, B. de Graaf<sup>1</sup>, E. Simons<sup>1</sup>, L. Govaerts<sup>1</sup>, S. Swagemakers<sup>2</sup>, J.M.H. Verkerk<sup>2</sup>, B.A. Oostra<sup>1</sup> and A.M. Bertoli-Avella<sup>1,3</sup>

<sup>1</sup>Department of Clinical Genetics, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; <sup>2</sup>Department of Bioinformatics, Erasmus Medical Center, Rotterdam, the Netherlands

### region on chromosome 5q14.1–q15



### Perspectives

- Genome scanning of familial cases
- Genome scanning of sporadic cases
- Candidate genes from animal models?

## CONCLUSIONS

POF 1-2% of women  
Xfra premutation ++  
Familial cases++  
Hope in genome wide studies

---

---

---

---

---

## GENES of MENOPAUSE



New Contraceptive Targets



New Infertility Treatment

---

---

---

---

---

D Dewailly, AC Reyss  
R Frydman, L Jacquesson  
P Bouchard, S Christin- Maître, N Bourcigaux,  
B Donadille, C Dupas

MF Portnoi, L Finkel, JP Siffroi  
G Tachdjian, A Aboura, G Rousseau

M Fellous, R Veitia, P Laissac  
M Lathrop, D Zelenika, S Heath

---

---

---

---

---